PDF(Pubmed)
Abstract：
Aims In this systematic review, we assessed the literature on the association between fibrinogen levels and stroke in patients with type 2 diabetes (T2D). Methods MEDLINE and Ovid searches of English reports were performed on the relation between fibrinogen, stroke, and T2D in humans. The search was completed on May 4, 2023. Studies were eligible when T2D patients ≥18 years had stroke confirmed by computed tomography or magnetic resonance imaging, plasma fibrinogen was measured, and a relation between fibrinogen and stroke in T2D patients was reported. Screening of reports and extraction of data were done independently by two authors, and study quality was assessed by predefined issues. Results Five studies of different designs were included. Three studies reported on significantly increased fibrinogen levels in T2D patients with stroke compared with T2D patients without stroke. Two studies did not observe a significant association between fibrinogen levels and stroke risk. Conclusion No consistent association was observed between fibrinogen levels and risk of stroke in T2D patients. Due to differences in study design, low sample size, and poorly defined study participants, larger and better-defined studies are needed to elucidate the role of fibrinogen as a stroke risk marker in T2D patients.
摘要：
在这篇系统综述中，我们评估了2型糖尿病(T2D)患者纤维蛋白原水平与卒中关系的文献.方法MEDLINE和Ovid检索有关纤维蛋白原之间关系的英文报告,中风,和人类的T2D。搜索于2023年5月4日完成。当≥18岁的T2D患者有计算机断层扫描或磁共振成像证实的卒中时，研究合格。测量血浆纤维蛋白原，并报道了纤维蛋白原与T2D患者卒中之间的关系。报告筛选和数据提取由两名作者独立完成，研究质量通过预定义的问题进行评估.结果共纳入5项不同设计的研究。三项研究报道，与没有中风的T2D患者相比，有中风的T2D患者的纤维蛋白原水平显着增加。两项研究未观察到纤维蛋白原水平与卒中风险之间的显着关联。结论在T2D患者中，纤维蛋白原水平与卒中风险之间未观察到一致的关联。由于研究设计的差异，样本量低，和定义不清的研究参与者，需要更大规模,更明确的研究来阐明纤维蛋白原作为T2D患者卒中风险标志物的作用.
